Current Headlines

  1. IQVIA And Medera To Advance Cardiac Gene Therapy And Human-Based Drug Discovery 8/4/2026

    IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms.

  2. Phylo And Chugai Partner To Advance AI Agents In Drug Discovery 8/4/2026

    Phylo, Inc. today announced a collaboration with Chugai Pharmaceutical Co., Ltd. to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows.

  3. Lilly's Olomorasib Receives U.S. FDA's Breakthrough Therapy Designation For The Treatment Of Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer 8/3/2026

    Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test.

  4. Aravax Awarded FDA Fast Track Designation For PVX108, A Next-Generation Immunotherapy For The Treatment Of Peanut Allergy 8/3/2026

    Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces it has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead product, PVX108 for the treatment of peanut allergy.

  5. U.S. FDA Grants Orphan Drug Designation To Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (NECs) 8/3/2026

    Zai Lab Limited today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), for the treatment of neuroendocrine carcinomas (NECs).

  6. Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI As A Separate Company To Commercialize And Expand Its Multi-Agent AI Co-Scientist Platform For The Transformation Of Medicine 8/3/2026

    Lantern Pharma Inc. a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma.

  7. Lupin Announces The Approval Of Diazepam Injection, USP In The United States 7/31/2026

    Global pharma major Lupin Limited (Lupin) today announced that it has received approval under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes.

  8. Henlius Announces IND Approval For Its Innovative PD-L1 ADC HLX43 In Combination With Bevacizumab ± Chemotherapy 7/31/2026

    Henlius today announced that the investigational new drug (IND) application for HLX43, the company’s innovative programmed death-ligand 1 (PD-L1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab with or without chemotherapy, for the treatment of advanced/metastatic solid tumors has been approved by China’s National Medical Products Administration (NMPA).

  9. HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation For AI-Designed Candidates 7/30/2026

    HKeyBio has established HKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration Program. The program supports AI drug-discovery teams in translating AI-generated targets, molecules and mechanism hypotheses into in vivo pharmacology, mechanism, PK/PD, biomarker and pre-IND translational evidence in autoimmune and allergy disease models.

  10. Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Sasineprocel (ANPD001) To Treat Parkinson's Disease 7/30/2026

    Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson's Disease (PD) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA).